{"id":"luspatercept-injectable-product","safety":{"commonSideEffects":[{"rate":null,"effect":"Bone pain"},{"rate":null,"effect":"Arthralgia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL3039545","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Luspatercept acts as a ligand trap by binding activin A and other TGF-β superfamily members that normally suppress erythroid maturation. By sequestering these inhibitory signals, it allows erythroid progenitor cells to progress through terminal differentiation stages, increasing red blood cell production and hemoglobin levels. This mechanism is particularly effective in conditions characterized by ineffective erythropoiesis.","oneSentence":"Luspatercept is an erythroid maturation agent that binds to and inhibits activin A and related proteins, promoting late-stage erythroid differentiation and hemoglobin production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:41:18.542Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Beta-thalassemia dependent on regular transfusions"},{"name":"Myelodysplastic syndrome with ring sideroblasts"}]},"trialDetails":[{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT04419649","phase":"PHASE2","title":"A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)","status":"RECRUITING","sponsor":"Takeda","startDate":"2020-08-19","conditions":"Myelodysplastic Syndromes, Cytopenia","enrollment":160},{"nctId":"NCT07331818","phase":"PHASE2","title":"Luspatercept in Patients Affected With Rare Inherited Anemias","status":"NOT_YET_RECRUITING","sponsor":"EuroBloodNet Association","startDate":"2026-01-15","conditions":"Hereditary Red Blood Cell Disorder (Disorder)","enrollment":45},{"nctId":"NCT04064060","phase":"PHASE3","title":"A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials","status":"RECRUITING","sponsor":"Celgene","startDate":"2019-08-12","conditions":"Myelodysplastic Syndromes (MDS), Beta-thalassemia, Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis","enrollment":665},{"nctId":"NCT05384691","phase":"PHASE2","title":"Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions","status":"RECRUITING","sponsor":"University of Leipzig","startDate":"2022-09-27","conditions":"Myelodysplastic Syndromes, Anemia","enrollment":213},{"nctId":"NCT05462548","phase":"PHASE4","title":"The Safety and Efficiency of Luspatercept in Chinese Adults With Transfusion Dependent β-thalassemia: a Real-world Study","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2022-07","conditions":"Thalassemia Major, Transfusion-dependent Anemia","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["luspatercept"],"phase":"marketed","status":"active","brandName":"Luspatercept Injectable Product","genericName":"Luspatercept Injectable Product","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Luspatercept is a protein-based inhibitor of transforming growth factor beta, used to treat various conditions including Hereditary Red Blood Cell Disorder, Myelodysplastic Syndromes, Cytopenia, and Beta-thalassemia. It is administered as an injectable product, with brand names including Reblozyl and Elritercept, and has been studied in clinical trials such as NCT07331818.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}